Clinical Study of OR for Second-line Treatment of Refractory MZL
Status:
Not yet recruiting
Trial end date:
2029-12-31
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to test the overall response rate of obrutinib combined
with rituximab (OR regimen) for second-line treatment of refractory marginal zone lymphoma.